CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of ...
—According to researchers in Germany, the presence of additional cytogenetic or molecular markers included in current risk stratification systems, rather than the presence or absence of a trisomy 8, ...
Q3 2025 Management View James Dentzer, President and CEO, emphasized continued progress in the TakeAim Lymphoma study evaluating emavusertib in combination with ibrutinib in primary CNS lymphoma ...
The FDA has approved revumenib (Revuforj; Syndax Pharmaceuticals) for patients 1 year and older with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 ( NPM1) mutation ...
The US FDA has approved the supplemental new drug application (sNDA) for revumenib (Revuforj) in the treatment of relapsed or refractory (R/R) mutant nucleophosmin 1 (m NPM1) acute myeloid leukemia ...
The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia with a ...
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study Patients with either MRD (≥1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback